Kimball Electronics (Nasdaq: KE) said it acquired Helvoet Polymer Technologies B.V., a Europe/India medical CDMO
Kimball Electronics (Nasdaq: KE) said it acquired Helvoet Polymer Technologies B.V., a Europe/India medical CDMO for microfluidics, diagnostics, and drug delivery, for €90m (~$103m) excluding adjustments. The deal is ~9x Helvoet 2026E adjusted EBITDA, expected accretive to fiscal 2027 adjusted earnings and to grow Kimball’s medical sales in the low double digits. Helvoet 2025 revenue was ~$56m.
How this was made
The 30-second read
Why it matters
The transaction is positioned as accretive to fiscal 2027 adjusted earnings and as a way to grow Kimball’s medical vertical, while adding manufacturing capacity in Europe and India and leveraging the Indianapolis facility for U.S. demand from existing Helvoet customers.
Market read
A newly disclosed, cash/credit-funded acquisition with explicit accretion and growth targets can re-rate expectations for Kimball’s medical CMO segment and near-term U.S. capacity utilization.
What to watch
Financing via revolver capacity and pro forma leverage consistency are mentioned but not quantified here; traders may need the 8-K for leverage, synergies, and integration cost assumptions.
Background
Kimball Electronics is expanding its medical CMO capabilities via the acquisition of Helvoet, a Europe-based CDMO with India operations focused on microfluidics, diagnostics, and drug delivery.
Ticker impact
Kimball (KE) announced it acquired Helvoet for ~€90M/$103M, targeting accretion to fiscal 2027 adjusted earnings and low-double-digit medical sales growth.
Near-term sentiment likely positive on deal value/strategic fit, but investors may scrutinize integration and leverage/financing details.
The article provides deal size, valuation multiple (~9x 2026E adjusted EBITDA), funding method (cash + revolver capacity), and explicit accretion/growth expectations for fiscal 2027.
Market effects
Could increase competitive pressure in medical CDMO/microfluidics outsourcing, potentially shifting attention toward vertically integrated medical manufacturing capacity.
Europe footprint expansion plus India production adds cross-region supply-chain relevance for healthcare manufacturing buyers.
Strengthens a global medical CMO platform narrative, which may influence how customers evaluate multi-site development/manufacturing partners.
Counterpoint
Accretion and low-double-digit sales growth targets may be optimistic; integration execution and customer program ramp timing could delay benefits.
Key entities
- public_companyKimball Electronics, Inc.
Nasdaq-listed manufacturer/CMO/EMS provider that announced the Helvoet acquisition and expects fiscal 2027 adjusted earnings accretion.
- private_or_foreign_companyHelvoet Polymer Technologies B.V.
Europe-based medical CDMO (microfluidics/diagnostics/drug delivery) with manufacturing in the Netherlands and India, acquired by Kimball.
- advisorMP Corporate Finance
Lead financial advisor to Helvoet in the transaction.
- advisorRoth Capital Partners
Exclusive financial advisor to Kimball Electronics in the transaction.
